Utilization and factors precluding the initiation of consolidative durvalumab in unresectable stage III non-small cell lung cancer

Durvalumab after concurrent chemoradiation has significantly improved survival in stage III non-small cell lung cancer (NSCLC). However, there is limited data evaluating the utilization and challenges to deliver durvalumab consolidation in the real world. We assessed the use of consolidative durvalu...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Radiother Oncol
Main Authors: Shaverdian, Narek, Offin, Michael D., Rimner, Andreas, Shepherd, Annemarie F., Wu, Abraham J., Rudin, Charles M., Hellmann, Matthew D., Chaft, Jamie E., Gomez, Daniel R.
Formato: Artigo
Idioma:Inglês
Publicado: 2019
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7523024/
https://ncbi.nlm.nih.gov/pubmed/31786421
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.radonc.2019.11.015
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares